Introduction to Clinical Benefit-Risk Assessment for the evaluation of (new) medicinal products

Available since June 2022
Dr. Pieter Niels (DCVMN Consultant) 

Commitments to monitoring of rare serious adverse events in the post-marketing period, in large populations, is a requirement for licensure due to safety reasons. Thus, the Benefit-Risk Assessment has become essential for the evaluation of (new) medicinal products. 

  • Self-Paced
  • EN